PriceTargets.com logo

Silence Therapeutics - SLN Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $57.20
  • Forecasted Upside: 731.40%
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$6.88 As of 12/20/2024 06:40 PM ET
▲ +0.54 (8.52%)

This chart shows the closing price for SLN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Silence Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SLN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SLN

Analyst Price Target is $57.20
▲ +731.40% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Silence Therapeutics in the last 3 months. The average price target is $57.20, with a high forecast of $75.00 and a low forecast of $40.00. The average price target represents a 731.40% upside from the last price of $6.88.

This chart shows the closing price for SLN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 6 polled investment analysts is to buy stock in Silence Therapeutics. This rating has held steady since May 2023, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/10/2024Chardan CapitalReiterated RatingBuy ➝ Buy$55.00 ➝ $55.00
12/9/2024HC WainwrightReiterated RatingBuy ➝ Buy$75.00 ➝ $75.00
12/2/2024BMO Capital MarketsReiterated RatingOutperform
11/19/2024William BlairReiterated RatingOutperform
11/15/2024HC WainwrightReiterated RatingBuy ➝ Buy$75.00 ➝ $75.00
11/14/2024Chardan CapitalReiterated RatingBuy ➝ Buy$55.00 ➝ $55.00
10/8/2024Morgan StanleyReiterated RatingOverweight ➝ Overweight$49.00 ➝ $49.00
9/3/2024Jefferies Financial GroupInitiated CoverageBuy$40.00
8/30/2024HC WainwrightReiterated RatingBuy ➝ Buy$75.00 ➝ $75.00
8/16/2024Chardan CapitalReiterated RatingBuy ➝ Buy$55.00 ➝ $55.00
6/28/2024Morgan StanleyBoost TargetOverweight ➝ Overweight$45.00 ➝ $49.00
6/28/2024Chardan CapitalBoost TargetBuy ➝ Buy$42.00 ➝ $55.00
6/27/2024HC WainwrightReiterated RatingBuy ➝ Buy$75.00 ➝ $75.00
6/20/2024HC WainwrightReiterated RatingBuy ➝ Buy$75.00 ➝ $75.00
5/31/2024HC WainwrightReiterated RatingBuy ➝ Buy$75.00 ➝ $75.00
5/24/2024HC WainwrightReiterated RatingBuy ➝ Buy$75.00 ➝ $75.00
5/17/2024HC WainwrightReiterated RatingBuy ➝ Buy$75.00
5/17/2024Chardan CapitalReiterated RatingBuy ➝ Buy$42.00 ➝ $42.00
4/22/2024Morgan StanleyReiterated RatingOverweight ➝ Overweight$45.00 ➝ $45.00
3/15/2024HC WainwrightReiterated RatingBuy ➝ Buy$75.00
3/14/2024Chardan CapitalBoost TargetBuy ➝ Buy$26.00 ➝ $42.00
3/14/2024Morgan StanleyBoost TargetOverweight ➝ Overweight$29.00 ➝ $45.00
2/22/2024HC WainwrightReiterated RatingBuy ➝ Buy$75.00
1/31/2024BMO Capital MarketsInitiated CoverageOutperform$67.00
1/18/2024HC WainwrightReiterated RatingBuy ➝ Buy$75.00
11/17/2023HC WainwrightLower TargetBuy ➝ Buy$80.00 ➝ $75.00
8/17/2023HC WainwrightReiterated RatingBuy ➝ Buy$80.00
8/17/2023Chardan CapitalReiterated RatingBuy ➝ Buy$26.00
7/24/2023Morgan StanleyReiterated RatingOverweight ➝ Overweight$20.00
5/8/2023Morgan StanleyInitiated CoverageOverweight$20.00
3/17/2023HC WainwrightReiterated RatingBuy$80.00
3/16/2023Chardan CapitalLower TargetBuy$29.00 ➝ $26.00
1/26/2023Robert W. BairdBoost Target$50.00 ➝ $53.00
12/9/2022Morgan StanleyInitiated CoverageEqual Weight$18.00
12/6/2022HC WainwrightLower TargetBuy$95.00 ➝ $80.00
11/17/2022Chardan CapitalLower TargetBuy$33.00 ➝ $29.00
3/31/2022Chardan CapitalInitiated CoverageBuy$33.00
3/22/2022HC WainwrightLower TargetBuy$100.00 ➝ $95.00
11/23/2021HC WainwrightReiterated RatingBuy$99.00
10/22/2021William BlairReiterated RatingBuy
4/30/2021William BlairReiterated RatingBuy
11/18/2020BTIG ResearchInitiated CoverageBuy
10/27/2020William BlairReiterated RatingOutperform
(Data available from 12/21/2019 forward)

News Sentiment Rating

0.90 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 2 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 5 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 6 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 5 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 1 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 7 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 7 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Silence Therapeutics logo
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.
Read More

Today's Range

Now: $6.88
Low: $6.16
High: $7.09

50 Day Range

MA: $12.42
Low: $6.33
High: $18.78

52 Week Range

Now: $6.88
Low: $5.81
High: $27.72

Volume

983,612 shs

Average Volume

274,802 shs

Market Capitalization

$205.90 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.05

Frequently Asked Questions

What sell-side analysts currently cover shares of Silence Therapeutics?

The following Wall Street sell-side analysts have issued research reports on Silence Therapeutics in the last twelve months: BMO Capital Markets, Chardan Capital, HC Wainwright, Jefferies Financial Group Inc., Morgan Stanley, and William Blair.
View the latest analyst ratings for SLN.

What is the current price target for Silence Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Silence Therapeutics in the last year. Their average twelve-month price target is $57.20, suggesting a possible upside of 731.4%. HC Wainwright has the highest price target set, predicting SLN will reach $75.00 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $40.00 for Silence Therapeutics in the next year.
View the latest price targets for SLN.

What is the current consensus analyst rating for Silence Therapeutics?

Silence Therapeutics currently has 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SLN will outperform the market and that investors should add to their positions of Silence Therapeutics.
View the latest ratings for SLN.

What other companies compete with Silence Therapeutics?

Other companies that are similar to Silence Therapeutics include Anavex Life Sciences, Immunome, Kura Oncology, Keros Therapeutics and Tyra Biosciences. Learn More about companies similar to Silence Therapeutics.

How do I contact Silence Therapeutics' investor relations team?

Silence Therapeutics' physical mailing address is 72 HAMMERSMITH ROAD, LONDON X0, W14 8TH. The company's listed phone number is 44-0-20-3457-6900. The official website for Silence Therapeutics is www.silence-therapeutics.com. Learn More about contacing Silence Therapeutics investor relations.